KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Basic): 2009-2025

Historic EPS (Basic) for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to -$1.25.

  • Novavax's EPS (Basic) fell 64.47% to -$1.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.11, marking a year-over-year increase of 196.35%. This contributed to the annual value of -$1.23 for FY2024, which is 77.26% up from last year.
  • Per Novavax's latest filing, its EPS (Basic) stood at -$1.25 for Q3 2025, which was down 289.39% from $0.66 recorded in Q2 2025.
  • In the past 5 years, Novavax's EPS (Basic) registered a high of $3.22 during Q1 2025, and its lowest value of -$11.31 during Q4 2021.
  • Its 3-year average for EPS (Basic) is -$0.37, with a median of -$0.76 in 2024.
  • As far as peak fluctuations go, Novavax's EPS (Basic) crashed by 1,483.33% in 2021, and later spiked by 406.67% in 2025.
  • Over the past 5 years, Novavax's EPS (Basic) (Quarterly) stood at -$11.31 in 2021, then skyrocketed by 79.75% to -$2.29 in 2022, then surged by 35.81% to -$1.47 in 2023, then soared by 64.63% to -$0.52 in 2024, then crashed by 64.47% to -$1.25 in 2025.
  • Its EPS (Basic) stands at -$1.25 for Q3 2025, versus $0.66 for Q2 2025 and $3.22 for Q1 2025.